 | • レポートコード：MRC2208A0070 • 出版社/出版日：Transparency Market Research / 2022年6月 • レポート形態：英文、PDF、346ページ • 納品方法：Eメール • 産業分類：医療機器 |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Transparency Market Research社の当調査資料では、世界の肺用薬物送達デバイス市場について広く調査・分析を行い、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、市場見通し、製品タイプ別（定量吸入器（MDI）、ドライパウダー吸入器（DPI）、ネブライザー）分析、用途別分析、流通チャネル別分析、地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米）分析、競争状況、企業情報などをまとめました。なお、当書に掲載されている企業情報には、Boehringer Ingelheim GmbH、Novartis AG、GlaxoSmithKline plc、Teva Pharmaceutical Industries Ltd.、AstraZeneca plc、Merck & Co., Inc.、MannKind Corporation、F. Hoffmann-La Roche Ltd.、Bristol-Myers Squibb Companyなどが含まれています。 ・序論 ・仮定・調査手法 ・エグゼクティブサマリー ・市場概要 ・市場動向 ・世界の肺用薬物送達デバイス市場規模：製品タイプ別（定量吸入器（MDI）、ドライパウダー吸入器（DPI）、ネブライザー） ・世界の肺用薬物送達デバイス市場規模：用途別 ・世界の肺用薬物送達デバイス市場規模：流通チャネル別 ・世界の肺用薬物送達デバイス市場規模：地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ） ・競争状況 ・企業情報 |
Pulmonary Drug Delivery Devices Market – Scope of Report
TMR’s report on the global pulmonary drug delivery devices market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global pulmonary drug delivery devices market for the period 2017–2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global pulmonary drug delivery devices market from 2022 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the pulmonary drug delivery devices market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global pulmonary drug delivery devices market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global pulmonary drug delivery devices market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global pulmonary drug delivery devices market.
The report delves into the competitive landscape of the global pulmonary drug delivery devices market. Key players operating in the global pulmonary drug delivery devices market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global pulmonary drug delivery devices market profiled in this report.
RESEARCH METHODOLOGY
The research methodology will be a combination of exhaustive primary and secondary research to analyze the market pulmonary drug delivery devices.
Secondary Research
Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.
Secondary research sources that we typically refer, but are not limited to:
Company websites, presentations, annual reports, white papers, technical paper, product brochure
Internal and external proprietary databases and relevant patents
National government documents, statistical databases, and market reports
News articles, press releases, and webcasts specific to companies operating in the market
Specific Secondary Sources:
Industry Sources:
WorldWideScience.org
Elsevier, Inc.
National Institutes of Health (NIH)
PubMed
NCBI
Department of Health Care Service
Trade Data Sources
Trade Map
UN Comtrade
Trade Atlas
Company Information
OneSource Business Browser
Hoover’s
Factiva
Bloomberg
Mergers & Acquisitions
Thomson Mergers & Acquisitions
MergerStat
Profound
Primary Research
During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.
We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:
Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
Helps in validating and strengthening secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies
Participants who typically take part in such a process include, but are not limited to:
Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
Purchasing/Sourcing managers, technical personnel, distributors
Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry verticals
List of primary participants, but not limited to:
Advanced Oncotherapy PLC
Danfysik A/S
Hitachi, Ltd.
IBA Worldwide
Mevion Medical Systems, Inc.
Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with “TMR Knowledge Repository”, which is updated every quarter.
Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:
Demographic Data: Healthcare expenditure, inflation rates, and others
Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities
Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.
レポート目次1. Preface
1.1. Report Scope
1.2. Market Segmentation
1.3. Research Highlights
2. Assumptions and Research Methodology
2.1. Assumptions
2.2. Research Methodology
3. Executive Summary
4. Market Overview
4.1. Product Type Overview
4.2. Key Industry Events
4.3. Market Opportunity Map
5. Market Dynamics
5.1. Drivers and Restraints Snapshot Analysis
5.2. Drivers
5.3. Restraints
5.4. Opportunity Analysis
5.5. Opportunities
5.6. Trends
5.7. Porter’s Five Forces Analysis
5.8. Value Chain Snapshot
6. Global Pulmonary Drugs Market Analysis, by Product Type
6.1. Key Findings
6.2. Introduction
6.3. Global Pulmonary Drug Delivery Devices Market Value Share Analysis, by Product Type
6.4. Global Pulmonary Drug Delivery Devices Market Forecast, by Product Type
6.4.1. Global Dry Powder Inhalers (DPIs) Market Revenue (US$ Mn) and Volume (Million Units), 2017–2031
6.4.2. Global Metered Dose Inhalers (MDIs) Market Revenue (US$ Mn) and Volume (Million Units), 2017–2031
6.4.3. Global Nebulizers Market Revenue (US$ Mn) and Volume (Million Units), 2017–2031
6.5. Global Pulmonary Drugs Market Attractiveness Analysis, by Product Type
6.6. Key Trends
7. Global Pulmonary Drug Delivery Devices Market Analysis, by Application
7.1. Key Findings
7.2. Introduction
7.3. Global Pulmonary Drug Delivery Devices Market Value Share Analysis, by Application, 2017 and 2031
7.4. Global Pulmonary Drug Delivery Devices Market Size (US$ Mn) and volume (Million Units) Forecast, by Application, 2017–2031
7.4.1. Global Asthma Market Revenue (US$ Mn) and volume (Million Units), 2017–2031
7.4.2. Global COPD Market Revenue (US$ Mn) and volume (Million Units), 2017–2031
7.4.3. Global Cystic Fibrosis Market Revenue (US$ Mn) and volume (Million Units), 2017–2031
7.4.4. Global Other Applications Market Revenue (US$ Mn) and volume (Million Units), 2017–2031
7.4.5. Global Pulmonary Drug Delivery Devices Market Attractiveness Analysis, by Application
7.5. Key Trends
8. Pulmonary Drug Delivery Devices Market Analysis, by Distribution Channel
8.1. Key Findings
8.2. Introduction
8.3. Global Pulmonary Drug Delivery Devices Market Value Share Analysis, by Distribution Channel, 2017 and 2031
8.4. Global Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Distribution Channel, 2017–2031
8.4.1. Global Retail Pharmacies Market Revenue (US$ Mn) and Volume (Million Units), 2017–2031
8.4.2. Global Hospital Pharmacies Market Revenue (US$ Mn) and Volume (Million Units), 2017–2031
8.4.3. Global E-commerce Market Revenue (US$ Mn) and Volume (Million Units), 2017–2031
8.5. Global Pulmonary Drug Delivery Devices Market Attractiveness Analysis, by Distribution Channel
9. Pulmonary Drug Delivery Devices Market Analysis, by Region
9.1. Global Scenario
9.2. Global Pulmonary Drug Delivery Devices Market Value Share Analysis By Region, 2017 and 2031
9.3. Global Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Region, 2017–2031
9.4. Global Pulmonary Drug Delivery Devices Market Attractiveness Analysis, by Region
10. North America Pulmonary Drug Delivery Devices Market Analysis
10.1. Key Findings
10.2. North America Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, 2017–2031
10.3. North America Pulmonary Drug Delivery Devices Market Size and Volume Y-o-Y Growth Projections, 2017–2031
10.4. North America Market Attractiveness Analysis, by Country, 2022–2031
10.5. North America Market Value Share Analysis, by Product Type, 2017 and 2031
10.6. North America Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Product Type, 2017–2031
10.7. North America Market Value Share Analysis, by Application, 2017 and 2031
10.8. North America Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Application, 2017–2031
10.9. North America Market Revenue Share Analysis, by Distribution Channel, 2017 and 2031
10.10. North America Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Distribution Channel, 2017–2031
10.11. North America Market Value Share Analysis, by Country, 2017 and 2031
10.12. North America Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Country, 2017–2031
10.13. North America Market Attractiveness Analysis, by Product Type, 2022–2031
10.14. North America Market Attractiveness Analysis, by Application, 2022–2031
10.15. North America Market Attractiveness Analysis, by Distribution Channel, 2022–2031
11. Europe Pulmonary Drug Delivery Devices Market Analysis
11.1. Key Findings
11.2. Europe Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, 2017–2031
11.3. Europe Pulmonary Drug Delivery Devices Market Size and Volume Y-o-Y Growth Projections, 2017–2031
11.4. Europe Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
11.5. Europe Market Value Share Analysis, by Product Type, 2017 and 2031
11.6. Europe Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Product Type, 2017–2031
11.7. Europe Market Value Share Analysis, by Application, 2017 and 2031
11.8. Europe Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Application, 2017–2031
11.9. Europe Market Revenue Share Analysis, by Distribution Channel, 2017 and 2031
11.10. Europe Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Distribution Channel, 2017–2031
11.11. Europe Market Value Share Analysis, by Country/Sub-region, 2017 and 2031
11.12. Europe Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Country, 2017–2031
11.13. Europe Market Attractiveness Analysis, by Product Type, 2022–2031
11.14. Europe Market Attractiveness Analysis, by Application, 2022–2031
11.15. Europe Market Attractiveness Analysis, by Distribution Channel, 2022–2031
12. Asia Pacific Pulmonary Drug Delivery Devices Market Analysis
12.1. Key Findings
12.2. Asia Pacific Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, 2017–2031
12.3. Asia Pacific Pulmonary Drug Delivery Devices Market Size and Volume Y-o-Y Growth Projections, 2017–2031
12.4. Asia Pacific Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
12.5. Asia Pacific Market Value Share Analysis, by Product Type, 2017 and 2031
12.6. Asia Pacific Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Product Type, 2017–2031
12.7. Asia Pacific Market Value Share Analysis, by Application, 2017 and 2031
12.8. Asia Pacific Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Application, 2017–2031
12.9. Asia Pacific Market Revenue Share Analysis, by Distribution Channel, 2017 and 2031
12.10. Asia Pacific Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Distribution Channel, 2017–2031
12.11. Asia Pacific Market Value Share Analysis, by Country/Sub-region, 2017 and 2031
12.12. Asia Pacific Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Country, 2017–2031
12.13. Asia Pacific Market Attractiveness Analysis, by Product Type, 2022–2031
12.14. Asia Pacific Market Attractiveness Analysis, by Application, 2022–2031
12.15. Asia Pacific Market Attractiveness Analysis, by Distribution Channel, 2022–2031
13. Latin America Pulmonary Drug Delivery Devices Market Analysis
13.1. Key Findings
13.2. Latin America Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, 2017–2031
13.3. Latin America Pulmonary Drug Delivery Devices Market Size and Volume Y-o-Y Growth Projections, 2017–2031
13.4. Latin America Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
13.5. Latin America Market Value Share Analysis, by Product Type, 2017 and 2031
13.6. Latin America Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Product Type, 2017–2031
13.7. Latin America Market Value Share Analysis, by Application, 2017 and 2031
13.8. Latin America Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Application, 2017–2031
13.9. Latin America Market Revenue Share Analysis, by Distribution Channel, 2017 and 2031
13.10. Latin America Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Distribution Channel, 2017–2031
13.11. Latin America Market Value Share Analysis, by Country/Sub-region, 2017 and 2031
13.12. Latin America Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Country, 2017–2031
13.13. Latin America Market Attractiveness Analysis, by Product Type, 2022–2031
13.14. Latin America Market Attractiveness Analysis, by Application, 2022–2031
13.15. Latin America Market Attractiveness Analysis, by Distribution Channel, 2022–2031
14. Middle East & Africa Pulmonary Drug Delivery Devices Market Analysis
14.1. Key Findings
14.2. Middle East & Africa Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, 2017–2031
14.3. Middle East & Africa Pulmonary Drug Delivery Devices Market Size and Volume Y-o-Y Growth Projections, 2017–2031
14.4. Middle East & Africa Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
14.5. Middle East & Africa Market Value Share Analysis, by Product Type, 2017 and 2031
14.6. Middle East & Africa Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Product Type, 2017–2031
14.7. Middle East & Africa Market Value Share Analysis, by Application, 2017 and 2031
14.8. Middle East & Africa Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Application, 2017–2031
14.9. Middle East & Africa Market Revenue Share Analysis, by Distribution Channel, 2017 and 2031
14.10. Middle East & Africa Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Distribution Channel, 2017–2031
14.11. Middle East & Africa Market Value Share Analysis, by Country/Sub-region, 2017 and 2031
14.12. Middle East & Africa Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Country/Sub-region, 2017–2031
14.13. Middle East & Africa Market Attractiveness Analysis, by Product Type, 2022–2031
14.14. Middle East & Africa Market Attractiveness Analysis, by Application, 2022–2031
14.15. Middle East & Africa Market Attractiveness Analysis, by Distribution Channel, 2022–2031
15. Competition Landscape
15.1. Global Pulmonary Drugs Market Share Analysis, by Company, 2015
15.2. Competitive Dashboard
15.3. Pipeline Snapshot
16. Company Profiles
16.1. Boehringer Ingelheim GmbH
16.1.1. Company Overview
16.1.2. Business Overview
16.1.3. Financial Overview
16.1.4. SWOT Analysis
16.1.5. Strategic Overview
16.2. Novartis AG
16.2.1. Company Overview
16.2.2. Business Overview
16.2.3. Financial Overview
16.2.4. SWOT Analysis
16.2.5. Strategic Overview
16.3. GlaxoSmithKline plc
16.3.1. Company Overview
16.3.2. Business Overview
16.3.3. Financial Overview
16.3.4. SWOT Analysis
16.3.5. Strategic Overview
16.4. AstraZeneca plc
16.4.1. Company Overview
16.4.2. Business Overview
16.4.3. Financial Overview
16.4.4. SWOT Analysis
16.4.5. Strategic Overview
16.5. Teva Pharmaceutical Industries Ltd.
16.5.1. Company Overview
16.5.2. Business Overview
16.5.3. Financial Overview
16.5.4. SWOT Analysis
16.5.5. Strategic Overview
16.6. Merck & Co., Inc.
16.6.1. Company Overview
16.6.2. Business Overview
16.6.3. Financial Overview
16.6.4. SWOT Analysis
16.6.5. Strategic Overview
16.7. MannKind Corporation
16.7.1. Company Overview
16.7.2. Business Overview
16.7.3. Financial Overview
16.7.4. SWOT Analysis
16.7.5. Strategic Overview
16.8. F. Hoffmann-La Roche Ltd.
16.8.1. Company Overview
16.8.2. Business Overview
16.8.3. Financial Overview
16.8.4. SWOT Analysis
16.8.5. Strategic Overview
16.9. Bristol-Myers Squibb Company
16.9.1. Company Overview
16.9.2. Business Overview
16.9.3. Financial Overview
16.9.4. SWOT Analysis
16.9.5. Strategic Overview
16.10. Mylan N.V.
16.10.1. Company Overview
16.10.2. Business Overview
16.10.3. Financial Overview
16.10.4. SWOT Analysis
16.10.5. Strategic Overview
16.11. Omron Corporation
16.11.1. Company Overview
16.11.2. Business Overview
16.11.3. Financial Overview
16.11.4. SWOT Analysis
16.11.5. Strategic Overview
16.12. 3M Healthcare
16.12.1. Company Overview
16.12.2. Business Overview
16.12.3. Financial Overview
16.12.4. SWOT Analysis
16.12.5. Strategic Overview
16.13. Sunovion Pharmaceuticals, Inc.
16.13.1. Company Overview
16.13.2. Business Overview
16.13.3. Financial Overview
16.13.4. SWOT Analysis
16.13.5. Strategic Overview
16.14. Koninklijke Philips N.V.
16.14.1. Company Overview
16.14.2. Business Overview
16.14.3. Financial Overview
16.14.4. SWOT Analysis
16.14.5. Strategic Overview
16.15. Gerresheimer AG
16.15.1. Company Overview
16.15.2. Business Overview
16.15.3. Financial Overview
16.15.4. SWOT Analysis
16.15.5. Strategic Overview
16.16. Bespak
16.16.1. Company Overview
16.16.2. Business Overview
16.16.3. Financial Overview
16.16.4. SWOT Analysis
16.16.5. Strategic Overview
16.17. AptarGroup, Inc.
16.17.1. Company Overview
16.17.2. Business Overview
16.17.3. Financial Overview
16.17.4. SWOT Analysis
16.17.5. Strategic Overview
16.18. SHL Group
16.18.1. Company Overview
16.18.2. Business Overview
16.18.3. SWOT Analysis
16.18.4. Strategic Overview
16.19. Nypro Healthcare Inc. (Jabil Circuit Inc.)
16.19.1. Company Overview
16.19.2. Business Overview
16.19.3. Financial Overview
16.19.4. SWOT Analysis
16.19.5. Strategic Overview
16.20. Hovione
16.20.1. Company Overview
16.20.2. Business Overview
16.20.3. Financial Overview
16.20.4. SWOT Analysis
16.20.5. Strategic Overview
16.21. Chiesi Farmaceutici S.p.A.
16.21.1. Company Overview
16.21.2. Business Overview
16.21.3. Financial Overview
16.21.4. SWOT Analysis
16.21.5. Strategic Overview
Table 01: Global Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (No. of Units) Forecast, by Product Type, 2017–2031
Table 02: Global Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Product Type, (Dry Powder Inhaler), 2017–2031
Table 03: Global Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Product Type, (Metered Dose Inhaler), 2017–2031
Table 04: Global Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Product Type, (Nebulizer), 2017–2031
Table 05: Global Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Application, 2017–2031
Table 06: Global Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Distribution Channel, 2017-2031
Table 07: Global Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (No. of Units) Forecast, by Region, 2017–2031
Table 08: North America Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Product Type, 2017–2031
Table 09: North America Pulmonary Drug Delivery Devices Volume (Million Units) Forecast, by Dry Powder Inhalers (Product) 2017–2031
Table 10: North America Pulmonary Drug Delivery Devices Volume (Million Units) Forecast, by Metered Dose Inhalers (Product) 2017–2031
Table 11: North America Pulmonary Drug Delivery Devices Volume (Million Units) Forecast, by Nebulizers (Product) 2017–2031
Table 12: North America Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Application, 2017–2031
Table 13: North America Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Distribution Channel 2017–2031
Table 14: North America Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Country, 2017–2031
Table 15: Europe Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Product Type, 2017–2031
Table 16: Europe Pulmonary Drug Delivery Devices Volume (Million Units) Forecast, by Product Type, (Dry Powder Inhaler) 2017–2031
Table 17: Europe Pulmonary Drug Delivery Devices Volume (Million Units) Forecast, by Product Type, (Metered Dose Inhaler) 2017–2031
Table 18: Europe Pulmonary Drug Delivery Devices and Volume (Million Units) Forecast, by Product Type, (Nebulizer) 2017–2031
Table 19: Europe Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Application, 2017–2031
Table 20: Europe Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Distribution Channel, 2017–2031
Table 21: Europe Pulmonary Drug Delivery Devices Market Size (US$ Mn) ) and Volume (Million Units) Forecast, by Country/Sub-region, 2017–2031
Table 22: Asia Pacific Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Product Type, 2017–2031
Table 23: Asia Pacific Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Product Type, (Dry Powder Inhaler) 2017–2031
Table 24: Asia Pacific Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Product Type, (Metered Dose Inhaler) 2017–2031
Table 25: Asia Pacific Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Product Type, (Nebulizer) 2017–2031
Table 26: Asia Pacific Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Application, 2017–2031
Table 27: Asia Pacific Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Distribution Channel, 2017–2031
Table 28: Asia Pacific Pulmonary Drug Delivery Devices Market Size (US$ Mn) ) and Volume (Million Units) Forecast, by Country/Sub-region, 2017–2031
Table 29: Latin America Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Product Type, 2017–2031
Table 30: Latin America Pulmonary Drug Delivery Devices Market Volume (Million Units) Forecast, by Product Type, (Dry Powder Inhaler) 2017–2031
Table 31: Latin America Pulmonary Drug Delivery Devices Market Volume (Million Units) Forecast, by Product Type, (Metered Dose Inhaler) 2017–2031
Table 32: Latin America Pulmonary Drug Delivery Devices Market Volume (Million Units) Forecast, by Product Type, (Nebulizer) 2017–2031
Table 33: Latin America Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Application, 2017–2031
Table 34: Latin America Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Distribution Channel, 2017–2031
Table 35: Latin America Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (Million Units) Forecast, by Country/Sub-region, 2017–2031
Table 36: Middle East & Africa Pulmonary Drug Delivery Devices Market Size Value (US$ Mn) and Volume (Million Units) Forecast, by Product Type, 2017–2031
Table 37: Middle East & Africa Pulmonary Drug Delivery Devices Market Volume (Million Units) Forecast, by Product Type, (Dry Powder Inhaler) 2017–2031
Table 38: Middle East & Africa Pulmonary Drug Delivery Devices Market Volume (Million Units) Forecast, by Product Type, (Metered Dose Inhaler) 2017–2031
Table 39: Middle East & Africa Pulmonary Drug Delivery Devices Market Volume (Million Units) Forecast, by Product Type, (Nebulizer) 2017–2031
Table 40: Middle East & Africa Pulmonary Drug Delivery Devices Market Size Value (US$ Mn) and Volume (Million Units) Forecast, by Application, 2017–2031
Table 41: Middle East & Africa Pulmonary Drug Delivery Devices Market Size Value (US$ Mn) and Volume (Million Units) Forecast, by Distribution Channel, 2017–2031
Table 42: Middle East & Africa Pulmonary Drug Delivery Devices Market Size (US$ Mn) ) and Volume (Million Units) Forecast, by Country/Sub-region, 2017–2031